Although SREBP1 suppression/inactivation is not associated with the adverse side effects of the presently available breast cancer prevention drugs, and endocrine therapies, its multifaceted biology needs to be further explored enabling selective SREBP1 modulators with favorable safety profiles. This evidence concerns the gene SREBF1 and breast carcinoma.